“As homeowners, our ultimate goal is to provide ourselves and our families with a safe place to live. Unfortunately, some homeowners don’t realize that some of the most substantial threats to their family’s well-being are not the physical ones – like intruders – but ones related to their health. Radon exposure is one of the most urgent issues a homeowner will face in keeping their loved ones safe, and the only way to protect them is by staying ahead of the threat.”
LUNGevity Partners with ASTRO to Issue RFA for Lung Cancer Research Grant
“WASHINGTON, Jan. 25, 2023 /PRNewswire/ — LUNGevity Foundation is partnering with the American Society for Radiation Oncology (ASTRO), the world’s largest radiation oncology society, to support radiation oncology research — an important area of study for the early detection and treatment of lung cancer.”
Agilent and Quest Diagnostics to Collaborate on Lung Cancer Diagnostic
“Agilent and Quest Diagnostics entered into an agreement to expand access to the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test. The ctDx FIRST is a single-site premarket approved test that is approved by FDA (1) as a companion diagnostic (CDx) to identify advanced non-small lung cancer (NSCLC) patients who may benefit from treatment with adagrasib (brand name Krazati). Adagrasib is a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy.”
High 20-Year Lung Cancer Survival Rates
“There is a high cure rate for screen-detected lung cancers, according to a study presented at the 2022 annual meeting of the Radiological Society of North America. Researchers estimated 20-year lung cancer-specific survival among 87,416 participants enrolled in a prospective, international, multicenter study of low-dose CT screening for lung cancer (I-ELCAP).”
FDA Approves Adjuvant Pembrolizumab in NSCLC
“The FDA has approved pembrolizumab (Keytruda) as an adjuvant treatment following resection and platinum-based chemotherapy for patients with stage IB (T2a ≥4 cm), II, or IIIA non–small cell lung cancer (NSCLC).”
Platinum Agents Appear Interchangeable in Small-Cell Lung Cancer
“Carboplatin and cisplatin are interchangeable in patients with limited-stage small-cell lung cancer (LS-SCLC) undergoing chemoradiation, a real-world study suggests.”
Trial to Investigate Novel Drug in KRAS-Mutant Lung Cancer
“A new study just launched that will study a novel drug, VIC-1911, either alone or given in combination with Lumakras (sotorasib) for patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC), according to VITRAC Therapeutics, the manufacturer of VIC-1911.”
